ESC 365 - Impact of SGLT2-inhibitors on cardiac function and structural changes in patients with heart failure and reduced ejection fraction

Back

ESC Professional Premium Access

Impact of SGLT2-inhibitors on cardiac function and structural changes in patients with heart failure and reduced ejection fraction - Results from the REWIN-HFrEF Study

Session: Novel insights into heart failure therapy

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Speaker: Doctor M. De Angelis (Brescia, IT)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Maria Grazia De Angelis

Spedali Civili, University Of Brescia, Brescia (Italy)

0 follower

7 more presentations in this session

Long term efficacy and safety of sacubitril/valsartan in chronic heart failure patients with reduced ejection fraction: a prospective real-world study.

Speaker: Doctor E. Brangi (Brescia, IT)

Real-world eligibility and tolerance of vericiguat in HFrEF patients: insights from a multicentric registry

Speaker: Doctor M. Mazzini (Brescia, IT)

Access

Abstract

Slides

Hemodynamic effect of angiotensin-neprilysin inhibition in diastolic dysfunction after acute myocardial infarction

Speaker: Mr P. Hartmund Frederiksen (Odense, DK)

The rhythm control strategy in patients with atrial fibrillation and heart failure with preserved or reduced ejection fraction: the single centre experience

Speaker: Doctor M. Pandrc (Belgrade, RS)

Clinical outcomes for patients with severe HFrEF diagnosed and treated in a community setting with the 'four pillars' of pharmacotherapy

Speaker: Doctor R. Bain (Grimsby, GB)

Access the full session

Novel insights into heart failure therapy

Speakers: Doctor M. De Angelis, Doctor E. Brangi, Doctor M. Mazzini, Mr P. Hartmund Frederiksen, Doctor M. Pandrc...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources